EUVIMEDEUVIMED entdecken
Crossref

Discovery of a potent and selective PARP1 degrader promoting cell cycle arrest via intercepting CDC25C-CDK1 axis for treating triple-negative breast cancer

Yiquan Wu, Mingfei Wu, Xiaoli Zheng, Hengyuan Yu, Xinfei Mao, Yuyuan Jin, Yanhong Wang, Ao Pang, Jingyu Zhang, Shenxin Zeng, Tengfei Xu, Yong Chen und 8 weitere

Bioorganic Chemistry · 2024

DOI: 10.1016/j.bioorg.2023.106952 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2024. Verfasst von Yiquan Wu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Hangzhou Institute of Innovative Medicine, Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou …. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Zhejiang Province Natural Science Foundation, Key Research and Development Program of Zhejiang Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PARP1 is a multifaceted component of DNA repair and chromatin remodeling, making it an effective therapeutic target for cancer therapy. The recently reported proteolytic targeting chimera (PROTAC) could effectively degrade PARP1 through the ubiquitin-proteasome pathway, expanding the therapeutic application of PARP1 blocking. In this study, a series of nitrogen heterocyclic PROTACs were designed and synthesized through ternary complex simulation analysis based on our previous work. Our efforts have resulted in a potent PARP1 degrader D6 (DC50 = 25.23 nM) with high selectivity due to nitrogen heterocyclic linker generating multiple interactions with the PARP1-CRBN PPI surface, specifically. Moreover, D6 exhibited strong cytotoxicity to triple negative breast cancer cell line MDA-MB-231 (IC50 = 1.04 µM). And the proteomic results showed that the antitumor mechanism of D6 was found that intensifies DNA damage by intercepting the CDC25C-CDK1 axis to halt cell cycle transition in triple-negative breast cancer cells. Furthermore, in vivo study, D6 showed a promising PK property with moderate oral absorption activity. And D6 could effectively inhibit tumor growth (TGI rate = 71.4 % at 40 mg/kg) without other signs of toxicity in MDA-MB-321 tumor-bearing mice. In summary, we have identified an original scaffold and potent PARP1 PROTAC that provided a novel intervention strategy for the treatment of triple-negative breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsHumansMiceAnimalsProteomicsCell ProliferationCell Cycle CheckpointsNitrogenCell Line, Tumorcdc25 PhosphatasesPoly (ADP-Ribose) Polymerase-1CDC2 Protein Kinase

Stichwörter der Autor:innen

CDC25C-CDK1 axisCycle arrestDNA lesionPARP1PROTACsTriple-negative breast cancer

Substanzen

NitrogenCDC25C protein, humancdc25 PhosphatasesPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1CDK1 protein, humanCDC2 Protein Kinase

Autor:innen und Institutionen

  • Hangzhou Institute of Innovative Medicine, Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
  • Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou 310058, China.
  • Key Laboratory of Advanced Drug Delivery Systems of Zhejiang Province, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
  • Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, Hangzhou Medical College, Hangzhou 310058, China.
  • Department of Pharmacy, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang, China.
  • Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hang…

Förderung

  • Zhejiang Province Natural Science Foundation
  • Key Research and Development Program of Zhejiang Province
  • National Natural Science Foundation of China

Zitieren

APA

Wu, Y., Wu, M., Zheng, X., Yu, H., Mao, X., Jin, Y., Wang, Y., Pang, A., Zhang, J., Zeng, S., Xu, T., Chen, Y., Zhang, B., Lin, N., Dai, H., Wang, Y., Yao, X., Dong, X., Huang, W., & Che, J. (2024). Discovery of a potent and selective PARP1 degrader promoting cell cycle arrest via intercepting CDC25C-CDK1 axis for treating triple-negative breast cancer. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2023.106952

Vancouver

Wu Y, Wu M, Zheng X, Yu H, Mao X, Jin Y, et al. Discovery of a potent and selective PARP1 degrader promoting cell cycle arrest via intercepting CDC25C-CDK1 axis for treating triple-negative breast cancer. Bioorganic Chemistry. 2024. doi:10.1016/j.bioorg.2023.106952

BibTeX
@article{Wu2024,
  author = {Wu, Yiquan and Wu, Mingfei and Zheng, Xiaoli and Yu, Hengyuan and Mao, Xinfei and Jin, Yuyuan and Wang, Yanhong and Pang, Ao and Zhang, Jingyu and Zeng, Shenxin and Xu, Tengfei and Chen, Yong and Zhang, Bo and Lin, Nengming and Dai, Haibin and Wang, Yuwei and Yao, Xiaojun and Dong, Xiaowu and Huang, Wenhai and Che, Jinxin},
  title = {Discovery of a potent and selective PARP1 degrader promoting cell cycle arrest via intercepting CDC25C-CDK1 axis for treating triple-negative breast cancer},
  journal = {Bioorganic Chemistry},
  year = {2024},
  doi = {10.1016/j.bioorg.2023.106952}
}
Kostenlos starten →